Alopecia

New sham-controlled trial finds niostem's at-home wearable using low-level electrical stimulation boosts hair density in men, with minimal adverse effects.

Maria Hordinsky, MD, breaks down phase 3 data that show topical clascoterone boosts male pattern hair growth for 12 months, targeting follicles without systemic hormonal adverse effects.

Weekly microneedling combined with daily topical 5% minoxidil produced statistically significant hair density gains in 40 women with female pattern hair loss.

The application is based on phase 3 UP-AA trial data showing significant hair regrowth in patients with severe alopecia areata.

Part A of Study '302' demonstrated statistically significant and clinically meaningful hair growth in men with androgenetic alopecia, with a favorable safety profile and no cardiac adverse events.

Combination therapy may be particularly beneficial for frontal hairline regrowth, a traditionally difficult area to treat.

REZPEG shows growing hair regrowth at 52 weeks in severe alopecia areata, with favorable safety, hinting at a new biologic alternative to JAKs.

Phase 3 data show clascoterone solution sustains hair regrowth for 12 months with vehicle-like safety, paving the way for a novel male androgenetic alopecia option.

Although dermatologists are not expected to routinely prescribe GLP-1 drugs, they are increasingly encountering cutaneous effects, especially hair loss and facial volume loss.

Experts discuss how clinicians translate clinical trial results into practical treatment decisions for alopecia areata.

The upcoming trial will assess an injectable formulation of Xvie, distinct from its currently available topical counterpart.

Experts discuss why alopecia areata should be viewed as a systemic condition with psychosocial consequences beyond visible hair loss.

Glynis Ablon, MD, FAAD, shares insights on diagnosing alopecia fast, managing aesthetic complications, and choosing evidence-based supplements.

Discover how Nutrafol Men 50+ addresses age-related hair loss in men, combining targeted ingredients for optimal scalp health and hair quality.

The new therapy targets age-related hair loss with a unique formula, promoting thicker, healthier hair for men over 50.

Aclaris Therapeutics' ATI-2138 shows promising rapid hair regrowth in severe alopecia areata models, highlighting its potential as a novel treatment option.

Recent research shows the long-term benefits and safety of low-level laser therapy for androgenetic alopecia.

Experts discuss real-world applications of JAK inhibitors for alopecia areata, emphasizing patient selection, psychosocial impacts, and personalized treatment strategies.

Discover how vitamin D receptor signaling influences hair follicle health and alopecia, revealing new therapeutic possibilities for hair loss management.

Legacy Healthcare has advanced Cinainu into a phase 3 study for alopecia areata, offering hope for effective, safe treatment without immunosuppression.

Spizuoco leads the inaugural DermVIP Summit, enhancing alopecia education for dermatology professionals through expert insights and innovative treatments.

Experts discuss real-world strategies for managing alopecia areata, emphasizing JAK inhibitors, psychosocial impacts, and personalized patient care approaches.

GT20029 shows promising results in treating androgenetic alopecia, enhancing hair density with minimal adverse effects in men after 12 weeks.

Cosmo Pharmaceuticals reveals promising phase 3 results for clascoterone 5% solution, showing significant hair growth improvement in alopecia.

Arash Mostaghimi, MD, MPH, FAAD, and experts discuss evolving treatment standards for alopecia areata, focusing on JAK inhibitors, patient-centered care, and future therapeutic innovations.